Eloxx Pharmaceuticals, Inc. 10-Q

Item 5. Other Information. (a) None. (b) None. 30 (c) During the three months ended June 30, 2026, no director or “officer” (as defined in Rule 16a-1(f) under the Exchange Act) of the Company adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K. 31 Item 6. E xhibits The following is a list of exhibits filed as part of this Quarterly Report on Form 10-Q. Where so indicated, exhibits that were previously filed are incorporated by reference. For exhibits incorporated by reference, the location of the exhibit in the previous filing is indicated. Incorporated by Reference Exhibit Number Exhibit Description Form File No. Exhibit Filing Date 3.1 Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Eloxx Pharmaceuticals, Inc., as filed with the Secretary of State of the State of Delaware on May 29, 2026 8-K 31326 3.1 June 1, 2026 10.1 Form of Amended and Restated Pre-Funded Warrant, pursuant to the Securities Purchase Agreement dated as of April 27, 2026 10+Q 31326 10.4 May 5, 2026 10.2 Form of Pre-Funded Warrant issued pursuant to the Underwriting Agreement, dated as of June 4, 2026 S-1 295651 10.60 June 4, 2026 10.3 Form of Pre-Funded Warrant issued pursuant to the Underwriting Agreement, dated as of June 8, 2026 S-1 295651 10.59 June 4, 2026 10.4 Amendment No.1 to the Registration Rights Agreement, dated as of June 1, 2026. S-1 295651 10.55 June 4, 2026 10.5 Eloxx Pharmaceuticals, Inc. 2018 Amended and Restated Equity Incentive Plan. S-1 295651 10.58 June 4, 2026 31.1* Certification of the Company’s Principal Executive Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a) of the Securities and Exchange Act of 1934, as amended, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. 31.2* Certification of the Company’s Principal Financial Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a) of the Securities and Exchange Act of 1934, as amended, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. 32.1** Certification of the Company’s Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. 32.2** Certification of the Company’s Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. 101.INS* Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the XBRL document. 101.SCH* Inline XBRL Taxonomy Extension Schema Document. 32 Incorporated by Reference Exhibit Number Exhibit Description Form File No. Exhibit Filing Date 101.CAL* Inline XBRL Taxonomy Extension Calculation Linkbase Document. 101.DEF* Inline XBRL Taxonomy Extension Definition Linkbase Document. 101.LAB* Inline XBRL Taxonomy Extension Label Linkbase Document. 101.PRE* Inline XBRL Taxonomy Extension Presentation Linkbase Document. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) * Filed herewith. ** This certification is being furnished solely to accompany this Quarterly Report on Form 10-Q pursuant to 18 U.S.C. Section 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference into any filing of the registrant under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date hereof, regardless of any general incorporation language in such filing. ‡ Confidential treatment requested under 17 C.F.R. §§200.80(b)(4) and 24b-2. The confidential portions of this exhibit have been omitted and are marked accordingly. The confidential portions have been filed separately with the Securities and Exchange Commission pursuant to the confidential treatment request. 33 SIGNAT URES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. ELOXX PHARMACEUTICALS, INC. Date: August 11, 2026 by: /s/ Daniel E. Geffken Daniel E. Geffken Interim Chief Financial Officer (Principal Financial Officer) 34